以岭药业：来曲唑原料药获上市申请批准

Group 1 - The company Yiling Pharmaceutical (002603) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the listing application of the chemical raw material drug Letrozole [1] - Letrozole is a highly effective, selective non-steroidal aromatase inhibitor used in the treatment of breast cancer [1] - The global breast cancer drug market is expected to reach USD 37.6 billion by 2025 and between USD 45 billion to USD 55 billion by 2030 [1] Group 2 - The incidence of breast cancer in China is rising annually, leading to an expected continuous growth in the demand for raw materials [1] - The company has invested approximately CNY 4.7 million in the research and development of Letrozole raw materials [1] - The approval enriches the company's product line and helps to expand its business scope, although it is not expected to have a significant impact on performance at this time [1]